Literature DB >> 21622014

Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.

Ourania Nicolatou-Galitis1, Erofili Papadopoulou, Triantafyllia Sarri, Polyxeni Boziari, Aikaterini Karayianni, Marie-Christine Kyrtsonis, Panagiotis Repousis, Vassilios Barbounis, Cesar A Migliorati.   

Abstract

OBJECTIVES: The objectives of this study were to define the incidence, pain, and healing in cancer patients treated with intravenous bisphosphonates. STUDY
DESIGN: The study included long-term follow-up of 99 bisphosphonate-using patients (group A) and conservative treatment of 67 patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ, group B) using 3 antibiotic schemes and oral hygiene.
RESULTS: The frequency of zoledronic acid single-agent use was 85.9% and 69.8% in group A and B, respectively. Median follow-up was 13 months (group A) and 16 months (group B). Two patients in group A developed BRONJ (2%). Of those with BRONJ in group B who completed follow-up, healing occurred in 14.9% (7/47) and pain subsided in 80.9% (38/47). Healing was significant in patients who received pamidronate followed by zoledronic acid (P = .023) and with BRONJ stages 0 and stage I (P = .003).
CONCLUSIONS: This case series suggests that oral hygiene and conservative antibiotic therapy play a role in healing and pain alleviation in BRONJ. Oral hygiene and follow-up may decrease incidence of BRONJ.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622014     DOI: 10.1016/j.tripleo.2011.02.037

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  19 in total

1.  Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw.

Authors:  Paula Baptistella de Lima; Veruska Lima Moura Brasil; Jurema Freire Lisboa de Castro; Flávia Maria de Moraes Ramos-Perez; Fábio Abreu Alves; Maria Luiza dos Anjos Pontual; Danyel Elias da Cruz Perez
Journal:  Support Care Cancer       Date:  2015-03-11       Impact factor: 3.603

2.  Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.

Authors:  Petra Rugani; Gero Luschin; Norbert Jakse; Barbara Kirnbauer; Uwe Lang; Stephan Acham
Journal:  Clin Oral Investig       Date:  2013-06-10       Impact factor: 3.573

3.  Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series.

Authors:  Petra Rugani; Stephan Acham; Barbara Kirnbauer; Astrid Truschnegg; Barbara Obermayer-Pietsch; Norbert Jakse
Journal:  Clin Oral Investig       Date:  2014-12-17       Impact factor: 3.573

4.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

5.  Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer.

Authors:  Naohisa Futamura; Hiroshi Urakawa; Eisuke Arai; Eiji Kozawa; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2013-01-04       Impact factor: 5.150

6.  The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.

Authors:  Erofili Papadopoulou; Ourania Nicolatou-Galitis; Ioannis Papassotiriou; Helena Linardou; Aikaterini Karagianni; Konstantinos Tsixlakis; Anthi Tarampikou; Kelly Michalakakou; Emmanouil Vardas; Dimitrios Bafaloukos
Journal:  Support Care Cancer       Date:  2019-04-17       Impact factor: 3.603

7.  Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings.

Authors:  Kaycee Walton; Tristan R Grogan; Edwin Eshaghzadeh; Danny Hadaya; David A Elashoff; Tara L Aghaloo; Sotirios Tetradis
Journal:  Dentomaxillofac Radiol       Date:  2018-06-28       Impact factor: 2.419

Review 8.  Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.

Authors:  Mampei Kawahara; Shinichiro Kuroshima; Takashi Sawase
Journal:  Int J Implant Dent       Date:  2021-05-14

9.  18F-Fluoride PET/CT Imaging of Medication-Related Osteonecrosis of the Jaw in Conservative Treatment-A Case Report.

Authors:  Christian Philipp Reinert; Christina Pfannenberg; Sergios Gatidis; Christian la Fougère; Konstantin Nikolaou; Sebastian Hoefert
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  Intravenous bisphosphonate-related osteonecrosis of the jaws: influence of coadjuvant antineoplastic treatment and study of buccodental condition.

Authors:  Maria Margaix-Muñoz; José Bagan; Rafael Poveda-Roda
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.